Ustekinumab

This publication has 19 references indexed in Scilit:

• Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis
  British Journal of Dermatology, 2009
• Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
  British Journal of Dermatology, 2008
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
  Published by Elsevier ,2008
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
  The Lancet, 2008
• Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
  Current Medical Research and Opinion, 2008
• Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany
  Dermatology, 2008
• Psoriasis
  New England Journal of Medicine, 2005
• A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis
  Journal of Investigative Dermatology, 2004
• Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
  The Journal of Experimental Medicine, 2004
• Expression of Interleukin-12 is Increased in Psoriatic Skin
  Journal of Investigative Dermatology, 1998